三期临床-话题@MedSci

#三期临床#

55篇内容 | 1922人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1991324, encodeId=965219913241c, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析, objectType=article, longId=196280, objectId=fe3c1962807f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe3c1962807f, replyNumber=0, likeNumber=83, createdTime=2021-05-27, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe3c1962807f, moduleTitle=J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe3c1962807f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991323, encodeId=91361991323bb, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行, objectType=article, longId=196013, objectId=c3f3196013e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f3196013e0, replyNumber=0, likeNumber=77, createdTime=2020-06-30, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f3196013e0, moduleTitle=科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f3196013e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991325, encodeId=99a41991325a4, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个, objectType=article, longId=199004, objectId=6cee19900470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cee19900470, replyNumber=0, likeNumber=101, createdTime=2021-07-21, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cee19900470, moduleTitle=8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cee19900470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=陈薇团队新冠疫苗海外开展三期临床试验, objectType=article, longId=200414, objectId=ced6200414c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced6200414c8, replyNumber=0, likeNumber=108, createdTime=2020-10-27, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced6200414c8, moduleTitle=陈薇团队新冠疫苗海外开展三期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced6200414c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991322, encodeId=1f501991322f0, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, objectType=article, longId=179498, objectId=3c141e949899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c141e949899, replyNumber=0, likeNumber=102, createdTime=2020-06-06, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c141e949899, moduleTitle=2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c141e949899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991319, encodeId=6b0d19913193e, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=联康集团**全生物表达新药三期临床试验申请获国家药监局受理, objectType=article, longId=154427, objectId=dd5415442ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd5415442ec3, replyNumber=0, likeNumber=110, createdTime=2018-12-15, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd5415442ec3, moduleTitle=联康集团**全生物表达新药三期临床试验申请获国家药监局受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd5415442ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991320, encodeId=fb5019913203b, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=礼来制药获得欧洲加速审批的软组织癌症药物Lartruvo三期临床失败, objectType=article, longId=159004, objectId=fb33159004d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb33159004d7, replyNumber=0, likeNumber=64, createdTime=2019-07-09, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb33159004d7, moduleTitle=礼来制药获得欧洲加速审批的软组织癌症药物Lartruvo三期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb33159004d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991317, encodeId=2392199131e50, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=三期临床使用干细胞移植在克罗恩病患者体中培育新的免疫系统, objectType=article, longId=146240, objectId=657c146240c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=657c146240c3, replyNumber=0, likeNumber=50, createdTime=2019-03-12, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=657c146240c3, moduleTitle=三期临床使用干细胞移植在克罗恩病患者体中培育新的免疫系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=657c146240c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991321, encodeId=99c819913210e, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=TransCon生长激素治疗儿童生长激素缺乏症三期临床研究核心结果公布, objectType=article, longId=161852, objectId=274016185262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=274016185262, replyNumber=0, likeNumber=75, createdTime=2019-07-14, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=274016185262, moduleTitle=TransCon生长激素治疗儿童生长激素缺乏症三期临床研究核心结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274016185262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991318, encodeId=03cd1991318db, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, objectType=article, longId=148032, objectId=3e5614803226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5614803226, replyNumber=0, likeNumber=115, createdTime=2019-01-19, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5614803226, moduleTitle=阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5614803226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991315, encodeId=745119913155a, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功, objectType=article, longId=125970, objectId=0df11259e00f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df11259e00f, replyNumber=0, likeNumber=76, createdTime=2018-03-05, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df11259e00f, moduleTitle=J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df11259e00f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991312, encodeId=730b199131238, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验, objectType=article, longId=115958, objectId=be6111595856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6111595856, replyNumber=0, likeNumber=85, createdTime=2018-07-05, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6111595856, moduleTitle=重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be6111595856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991311, encodeId=0dc419913118e, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), objectType=article, longId=106852, objectId=5c6a10685217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c6a10685217, replyNumber=0, likeNumber=75, createdTime=2017-12-17, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c6a10685217, moduleTitle=Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c6a10685217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991316, encodeId=c8e6199131612, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=抗花生过敏药物三期临床成功, objectType=article, longId=130285, objectId=8a1713028504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1713028504, replyNumber=0, likeNumber=80, createdTime=2018-09-14, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1713028504, moduleTitle=抗花生过敏药物三期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1713028504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991314, encodeId=938d19913142e, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床, objectType=article, longId=125937, objectId=16d012593e87, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d012593e87, replyNumber=0, likeNumber=84, createdTime=2018-09-16, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d012593e87, moduleTitle=全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d012593e87)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991313, encodeId=b630199131346, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=LMTX (R)的第二次三期临床研究结果在《阿尔茨海默病期刊》上发表, objectType=article, longId=121575, objectId=04e61215e595, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04e61215e595, replyNumber=0, likeNumber=75, createdTime=2018-08-04, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04e61215e595, moduleTitle=LMTX (R)的第二次三期临床研究结果在《阿尔茨海默病期刊》上发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04e61215e595)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991310, encodeId=8d351991310fe, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=复方丹参滴丸（T89）完成美国FDA三期临床试验, objectType=article, longId=85448, objectId=53958544817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53958544817, replyNumber=0, likeNumber=83, createdTime=2017-04-20, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53958544817, moduleTitle=复方丹参滴丸（T89）完成美国FDA三期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53958544817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991309, encodeId=28e0199130968, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果, objectType=article, longId=83296, objectId=dcc38329618, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc38329618, replyNumber=0, likeNumber=71, createdTime=2017-03-23, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc38329618, moduleTitle=药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcc38329618)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991308, encodeId=764719913088a, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=JCO：RADIANT-3研究：随机三期临床研究探索依维莫司治疗晚期胰腺内分泌瘤患者的OS与循环生物标志物, objectType=article, longId=81989, objectId=52d8819890c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52d8819890c, replyNumber=0, likeNumber=76, createdTime=2017-10-19, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52d8819890c, moduleTitle=JCO：RADIANT-3研究：随机三期临床研究探索依维莫司治疗晚期胰腺内分泌瘤患者的OS与循环生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52d8819890c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991306, encodeId=f6ca19913061d, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, objectTitle=阿尔茨海默病新药LMTX三期临床试验失败，30年努力是否白费？, objectType=article, longId=74035, objectId=296ce403503, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=296ce403503, replyNumber=0, likeNumber=71, createdTime=2016-12-27, rootId=0, userName=楚秀娟, userId=e9ed371, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=296ce403503, moduleTitle=阿尔茨海默病新药LMTX三期临床试验失败，30年努力是否白费？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=296ce403503)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

三期临床

2020-05-29

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

J Immunother Cancer：抗PD1单药治疗头颈部鳞状细胞癌患者三期临床试验的比较分析

2021-05-27

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

科兴生物新冠病毒疫苗初步显示安全有效！三期临床试验将在中国和巴西进行

2020-06-30

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

8月8日全球新冠肺炎（COVID-19）疫情简报，确诊超1952万，6种疫苗进入三期临床试验，中国占3个

2021-07-21

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

陈薇团队新冠疫苗海外开展三期临床试验

2020-10-27

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

2019 WCLC | 五年五倍! 全球NSCLC免疫治疗三期临床研究5年生存结果公布—CM017/057汇总分析

2020-06-06

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

联康集团**全生物表达新药三期临床试验申请获国家药监局受理

2018-12-15

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

礼来制药获得欧洲加速审批的软组织癌症药物Lartruvo三期临床失败

2019-07-09

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

三期临床使用干细胞移植在克罗恩病患者体中培育新的免疫系统

2019-03-12

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

TransCon生长激素治疗儿童生长激素缺乏症三期临床研究核心结果公布

2019-07-14

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

阿斯利康狼疮药物anifrolumab未能到达三期临床试验的主要终点

2019-01-19

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

J Clin Oncol：新药彭溴利唑，治疗中晚期癌症，三期临床试验成功

2018-03-05

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

重磅：国家重大新药项目“皮卡狂犬病疫苗”开启国际多中心三期临床试验

2018-07-05

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

Keytruda治疗头颈癌三期临床试验未达主要终点(Keynote-040研究)

2017-12-17

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

抗花生过敏药物三期临床成功

2018-09-14

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床

2018-09-16

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

LMTX (R)的第二次三期临床研究结果在《阿尔茨海默病期刊》上发表

2018-08-04

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

复方丹参滴丸（T89）完成美国FDA三期临床试验

2017-04-20

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

药华医药将于ASH年会发表治疗PV新药Proud-PV三期临床试验结果

2017-03-23

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

JCO：RADIANT-3研究：随机三期临床研究探索依维莫司治疗晚期胰腺内分泌瘤患者的OS与循环生物标志物

2017-10-19

楚秀娟 (审核中...)

前往app查看评论内容

#三期临床#

阿尔茨海默病新药LMTX三期临床试验失败，30年努力是否白费？

2016-12-27

科室
- - 订阅+
  - 更多科室
工具
服务